PORTLAND, Maine, May 19, 2022 (GLOBE NEWSWIRE) — ImmuCell Corporation (ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets practical, scientifically proven products that improve the health and productivity of dairy and beef cattle, announced today that its 2022 annual meeting of shareholders be held virtually.
In light of the ongoing COVID-19 pandemic and in an effort to protect the health and safety of the Company’s shareholders, employees and communities, the Annual Meeting will be held via remote communication in the form of a live audio webcast and conference call rather than an in-person event.
The Annual Meeting will be Wednesday, June 15, 2022 at 3:00 p.m. ET. Registered shareholders of the Company’s common stock as of the close of business on April 14, 2022 are invited to participate in the annual meeting by accessing the live audio webcast at https://app.webinar.net/ xlyOrODnJq3 or by dialing (844) 855-9502 toll free or (412) 317-5499 for international access. Participation in the informal question-and-answer session, which will take place after the formal closing of the meeting, will be limited to connecting by conference call. Participation via live audio webcast will be in listen-only mode. A replay of the meeting will be available for seven days after the meeting by dialing (877) 344-7529 toll-free or (412) 317-0088 for international access, using the replay passcode: 1949353.
Shareholders, regardless of their intent to attend the virtual-only meeting, are encouraged to vote and submit their proxies prior to the annual meeting using one of the methods described in the proxy materials. Shareholders can continue to use the voting instruction form or proxy card provided, and no further action is required from shareholders who have already submitted their proxy. Shareholders wishing to vote at the annual meeting (instead of voting by proxy) should contact the company’s voting inspector prior to the meeting at (207) 878-2770 ext. 0 or by e-mail to: [email protected] organize the vote in session.
Investors are encouraged to review the company’s Form 10-Q for the three-month period ended March 31, 2022 which was filed with the SEC on Thursday, May 12, 2022 and its updated corporate presentation slide deck which provides an overview of the company’s activities. and is available under the “Investors” tab of the Company’s website at www.immucell.com, or on request from the Company. For more information about the annual meeting, including matters to vote on at the annual meeting, please see the company’s notice of annual meeting of shareholders and its statement of proxy, which are available, as well as the 2021 Annual Report on Form 10-K, at www.immucell.com.
ImmuCell Corporation ( CICC) is to create practical, scientifically proven products that improve the health and productivity of dairy and beef cattle. ImmuCell manufactures and markets first defense®providing Immediate immunity™ to newborn dairy and beef calves, and is in the final stages of development To hold onto®, a new treatment for subclinical mastitis in dairy cows without the requirement of milk rejection that offers an alternative to traditional antibiotics. Press releases and other information about the Company are available at: http://www.immucell.com.
Michael F. Brigham, President and CEO
Joe Diaz, Robert Blum and Joe Dorame
Lytham Partners, LLC
Caution Regarding Forward-Looking Statements (Safe port Statement):
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statement relating to: our projects and strategies for our company; projections of future financial or operational performance; the timing and outcome of pending or anticipated regulatory approvals; factors that may affect the dairy and beef industries and future demand for our products; the extent, nature and duration of the COVID-19 pandemic and its consequences, as well as their direct and indirect impacts on our production activities, results of operations and financial condition, as well as on customers and markets we serve; the impact of Russia’s unprovoked military invasion of Ukraine and attack on its people on the global economy, including inflation and the price and availability of grain and oil; the impact of global supply chain disruptions on our ability to timely and cost-effectively obtain all of the supplies and components we need to manufacture our products; difficulties in attracting and retaining the necessary staff in the current employment environment; the impact of inflation and rising interest rates on our operating expenses and financial results; the scope and timing of ongoing and future product development work and commercialization of our products; future costs of product development efforts; the estimated prevalence rate of subclinical mastitis and the level of producer interest in treating subclinical mastitis given current economic and market conditions; the expected efficacy of new products; estimates of the market size for our products; future market share and revenues generated by current products and products still under development; our ability to increase production and reduce cost of goods sold per unit; the future adequacy of our own manufacturing facilities or those of third parties with whom we have contractual relationships to meet demand for our products on a timely basis; the impacts of backlogs on customer relationships; the anticipated costs (or time to completion) of planned expansions of our manufacturing facilities and the sufficiency of our funds available for such projects; the continued availability to us on reasonable terms from third party suppliers of critical products or services; the robustness of our manufacturing processes and associated technical issues; estimates of our production capacity, efficiency and yield, which are highly subject to biological variability and the product format mix of our sales; the future adequacy of our working capital and the availability and cost of third-party financing; future regulatory requirements relating to our products; expense ratios and future margins; future compliance with banking covenants; costs associated with maintaining compliance with current good manufacturing practice (cGMP) regulations in our current operations and achieving such compliance for our nisin drug substance and drug product production facilities; our effectiveness in competing with our competitors in our existing and anticipated product markets; the profitability of additional sales and marketing expenditures and resources; anticipated changes in our manufacturing capabilities and efficiency; the value of our net deferred tax assets; projections of depreciation expense and its impact on income for accounting and tax purposes; and any other statements that are not historical facts. Forward-looking statements can be identified by the use of words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “should”, “could”, ” should”, “will”, “plan”, “believe”, “estimate”, “target”, “plan”, “anticipate”, “seek” and similar words and expressions. In addition, there can be no assurance that future developments affecting us will be those anticipated by us. Such statements involve risks and uncertainties, including, but not limited to, the risks and uncertainties relating to: difficulties or delays in development, testing, regulatory approval, production and marketing of our products (including first defense® range of products and To hold onto®), competition within our intended product markets, customer acceptance of our new and existing products, product performance, alignment between our manufacturing resources and product demand (including the consequences of delays or the accumulation of excess inventory), the uncertainty associated with the timing and volume of customer orders as we exit from an extended backlog, the negative impacts of supply chain disruptions on our operations and our relationships with customers, our dependence on third parties for financial support, products and services, our small size and dependence on key personnel, changes in laws and regulations, decision-making and delays by regulatory authorities, a recurrence of inflation and its impact on our customers’ ordering habits, currency values and fluctuations and other risks detailed from time to time in our filings with the Securities and Exchange Commission (SEC), including our quarterly reports on Form 10-Q, our annual reports on Form 10-K and our current reports on Form 8- K. These statements involve risks and uncertainties and are based on our current expectations, but actual results may differ materially due to a variety of factors, including the risk factors summarized above.